October 4, 2018 10:03 AM EDT
R&D

Eli Lil­ly ush­ers up-and-com­ing GIP/GLP-1 drug in­to PhI­II as No­vo Nordisk ri­val wows with im­pres­sive re­sults

Amber Tong

With No­vo Nordisk’s GLP-1 drug Ozem­pic (semaglu­tide) on its tail, Eli Lil­ly has round­ed up some mid-stage da­ta to show it has the right can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times